The lack of effective therapies to limit neurovascular injury in ischemic retinopathy is a major
clinical problem. This study aimed to examine the role of ureohydrolase enzyme, arginase 1 …

Retinal ischemia is a major cause of visual impairment and blindness and is involved in
various disorders including diabetic retinopathy, glaucoma, optic neuropathies and …

Our previous studies have implicated expression of the mitochondrial isoform of the
arginase enzyme arginase 2 (A2) in neurovascular injury during ischemic retinopathies. The …

Current therapies for treatment of proliferative retinopathy focus on retinal
neovascularization (RNV) during advanced disease and can trigger adverse side-effects …

Abstract Arginase 1 (A1) is the enzyme that hydrolyzes the amino acid, L-arginine, to
ornithine and urea. We have previously shown that A1 deletion worsens retinal ischemic …

Abstract The enzyme arginase 1 (A1) hydrolyzes the amino acid arginine to form L-ornithine
and urea. Ornithine is further converted to polyamines by the ornithine decarboxylase (ODC) …

Objective Retinal ischemic disease is a major cause of vision loss. Current treatment options
are limited to late-stage diseases, and the molecular mechanisms of the initial insult are not …

Optic neuritis is a major clinical feature of multiple sclerosis (MS) and can lead to temporary
or permanent vision loss. Previous studies from our laboratory have demonstrated the …

Background Hyperoxia exposure of premature infants causes obliteration of the immature
retinal microvessels, leading to a condition of proliferative vitreoretinal neovascularization …

Ischemic retinopathies, such as diabetic retinopathy (DR), retinopathy of prematurity and
retinal vein occlusion are a major cause of blindness in developed nations worldwide. Each …